SC-DARIC33

N/A

Report date: 2025/10/28 20:00:08

Base Information

Drug NameSC-DARIC33
Drug Alias NameCD33 targeted regulatable CAR TCD-33 targeted regulatable CAR TSC-DARIC33DARIC-33
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsCytotoxic T lymphocytes replacementsAnti-Myeloid cell surface antigen CD33
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesGenetix Biotherapeutics IncSeattle Children'S Hospital2seventy Bio Inc
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A